BioCentury | Mar 12, 2019
Financial News

InventisBio raises $70M series C to advance early stage pipeline

...SZSE:300558) exclusive rights to develop and commercialize D-0316 in China, including Hong Kong, and Taiwan. D-0316...
...series B in 2017 (see "InventisBio Raises $19M in Series B Round" ). Hongjiang Li, Staff Writer D-0316 D-0502 InventisBio...
BioCentury | Jan 4, 2019
Company News

Betta Pharma signs China deals with InventisBio, Merus

...Inc. (Shanghai, China) granted Betta Pharmaceuticals Co. Ltd (SZSE:300558) exclusive rights to develop and commercialize D-0316...
...$33.5 million), and is eligible for sales milestones and tiered royalties based on annual sales. D-0316...
...China Merus N.V., Utrecht, the Netherlands Betta Pharmaceuticals Co. Ltd (SZSE:300558), Hangzhou, China Business: Cancer Hongjiang Li D-0316 Betta...
Items per page:
1 - 2 of 2